Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Small Cell Lung Carcinoma 1Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Cisplatin 31Fluorouracil 24Paclitaxel 19Radiotherapy 15Docetaxel 11Esophagectomy 8Radiation 7Neoadjuvant Therapy 7Carboplatin 7Irinotecan 6Oxaliplatin 5Leucovorin 5Capecitabine 5sintilimab 4pembrolizumab 4camrelizumab 4TP protocol 4Surgical Procedures, Operative 4Drug Therapy 4Chemotherapy, Adjuvant 4Trastuzumab 3Immunotherapy 3Epirubicin 3Chemoradiotherapy 3tislelizumab 2nimotuzumab 2S 1 (combination) 2Radiotherapy, Adjuvant 2Platinum Compounds 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Neoplasms × irinotecan sucrosofate × Clear all
NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Sun Yat-sen University

Phase 3 Not yet recruiting
360 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡